Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

Next Previous
Trial Profile

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Trabectedin (Primary) ; F-18 fluorothymidine
  • Indications Ewing's sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SARC037

Most Recent Events

  • 01 Jun 2026 Primary endpoint has been met. (Phase I The recommended dose (RD) of trabectedin administered in combination with low dose irinotecan)
  • 01 Jun 2026 Primary endpoint has been met. (Phase 2 To determine anti-tumor activity of the combination trabectedin and low-dose irinotecan)
  • 01 Jun 2026 Results published in the Nature Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top